Sirolimus for dilated cardiomyopathy with KSHV infection
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests whether the drug sirolimus (rapamycin) can help people with dilated cardiomyopathy who also have a specific virus (KSHV) in their blood. It aims to see if sirolimus can improve heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with dilated cardiomyopathy (a condition where the heart is enlarged and pumps less effectively).
- You have tested positive for a virus called Kaposi sarcoma-associated herpesvirus (KSHV) in your blood.
- You are not allergic to sirolimus (rapamycin) or similar drugs.
- You are not pregnant or planning to become pregnant and are not taking part in another drug trial within the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
This study tests whether a low dose or a high dose of sirolimus (a drug that stops abnormal cell growth) combined with prednisolone (a steroid) works better for children with a rare, aggressive vascular tumor called KHE that also causes low blood platelets (KMP). The goal is to find the safest and most effective dose to help shrink the tumor and improve blood counts.
This study looks at different ways to stop taking sirolimus for children with KHE, a rare blood vessel tumor. It helps find the best plan to prevent the tumor from coming back after treatment.
This trial studies whether sirolimus (Rapamune®) can reduce problems from severe arteriovenous malformations (tangled blood vessel connections). It may help shrink the abnormal vessels or improve symptoms, by testing the medicine in people with certain AVM types.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
Hear when a new Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.